van Wijk Jeroen P H, Cabezas Manuel Castro
Department of Internal Medicine, University Medical Center, P.O. Box 85500, 3508 GA Utrecht, The Netherlands.
Int J Vasc Med. 2012;2012:201027. doi: 10.1155/2012/201027. Epub 2011 Aug 22.
The use of combination antiretroviral therapy (CART) in HIV-infected patients has resulted in a dramatic decline in AIDS-related mortality. However, mortality due to non-AIDS conditions, particularly cardiovascular disease (CVD) seems to increase in this population. CART has been associated with several metabolic risk factors, including insulin resistance, low HDL-cholesterol, hypertriglyceridemia and postprandial hyperlipidemia. In addition, HIV itself, as well as specific antiretroviral agents, may further increase cardiovascular risk by interfering with endothelial function. As the HIV population is aging, CVD may become an increasingly growing health problem in the future. Therefore, early diagnosis and treatment of cardiovascular risk factors is warranted in this population. This paper reviews the contribution of both, HIV infection and CART, to insulin resistance, postprandial hyperlipidemia and cardiovascular risk in HIV-infected patients. Strategies to reduce cardiovascular risk are also discussed.
在人类免疫缺陷病毒(HIV)感染患者中使用联合抗逆转录病毒疗法(CART)已导致与艾滋病相关的死亡率大幅下降。然而,该人群中因非艾滋病相关病症导致的死亡率,尤其是心血管疾病(CVD)似乎有所上升。CART与多种代谢风险因素相关,包括胰岛素抵抗、高密度脂蛋白胆固醇水平低、高甘油三酯血症和餐后高脂血症。此外,HIV本身以及特定的抗逆转录病毒药物可能通过干扰内皮功能进一步增加心血管疾病风险。随着感染HIV的人群老龄化,CVD在未来可能会成为一个日益严重的健康问题。因此,对该人群进行心血管疾病风险因素的早期诊断和治疗是必要的。本文综述了HIV感染和CART对HIV感染患者胰岛素抵抗、餐后高脂血症和心血管疾病风险的影响。还讨论了降低心血管疾病风险的策略。